Your session is about to expire
← Back to Search
Efgartigimod for Post-COVID-19 POTS (POTS Trial)
POTS Trial Summary
This trial looks at how safe and effective a drug is for people with post-COVID-19 postural orthostatic tachycardia syndrome (POTS).
POTS Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowPOTS Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.POTS Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am a woman who can have children and have a negative pregnancy test.
- Group 1: Efgartigimod
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has the Food and Drug Administration authorized Efgartigimod for commercial use?
"Given the lack of proof-of-concept data on Efgartigimod's efficacy, its safety score was a 2."
To what degree is the research sample size expanding?
"Affirmative, the information hosted on clinicaltrials.gov reveals that this study is actively searching for participants. It was initially posted on June 16th 2023 and has been amended as recently as June 22nd 2023. The trial requires 38 individuals to be recruited from one medical centre."
Are there still available slots for participants in this research?
"Affirmative. Clinicaltrials.gov has verified that this medical trial is still recruiting participants, with an initial posting on June 16th 2023 and a recent edit from the 22nd of the same month. In total 38 patients will be recruited across 1 site."
Share this study with friends
Copy Link
Messenger